Solubility enhancement of Cox-2 inhibitors using various solvent systems
- PMID: 14621965
- PMCID: PMC2750626
- DOI: 10.1208/pt040333
Solubility enhancement of Cox-2 inhibitors using various solvent systems
Abstract
This study examined the solubility enhancement of 4 cox-2 inhibitors, celecoxib, rofecoxib, meloxicam, and nimesulide, using a series of pure solvents and solvent mixtures. Water, alcohols, glycols, glycerol, and polyethylene glycol 400 (PEG 400) were used as solvents and water-ethanol, glycerol-ethanol, and polyethylene glycol-ethanol were used as mixed-solvent systems. A pH-solubility profile of drugs was obtained in the pH range 7.0 to 10.9 using 0.05 M glycine-sodium hydroxide buffer solutions. Lower alcohols, higher glycols, and PEG 400 were found to be good solvents for these drugs. The aqueous solubility of celecoxib, rofecoxib, and nimesulide could be enhanced significantly by using ethanol as the second solvent. Among the mixed-solvent systems, PEG 400- ethanol system had highest solubilization potential. In the case of meloxicam and nimesulide, solubility increased significantly with increase in pH value. Physico-chemical properties of the solvent such as polarity, intermolecular interactions, and the ability of the solvent to form a hydrogen bond with the drug molecules were found to be the major factors involved in the dissolution of drugs by pure solvents. The greater the difference in the polarity of the 2 solvents in a given mixed solvent, the greater was the solubilization power. However, in a given mixed-solvent system, the solubilization power could not be related to the polarity of the drugs. Significance of the solubility data in relation to the development of formulations has also been discussed in this study.
Similar articles
-
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.Eur Ann Allergy Clin Immunol. 2004 Jun;36(6):215-8. Eur Ann Allergy Clin Immunol. 2004. PMID: 15329003 Clinical Trial.
-
[Selective cyclooxygenase 2 inhibitors (COX-2)].Postepy Hig Med Dosw. 2001;55(2):287-302. Postepy Hig Med Dosw. 2001. PMID: 11468975 Review. Polish.
-
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.J Med Chem. 2004 Jan 29;47(3):550-7. doi: 10.1021/jm030912m. J Med Chem. 2004. PMID: 14736236
-
Uterine relaxant effects of cyclooxygenase-2 inhibitors in vitro.Obstet Gynecol. 2001 Oct;98(4):563-9. doi: 10.1016/s0029-7844(01)01522-8. Obstet Gynecol. 2001. PMID: 11576568 Clinical Trial.
-
The new NSAIDs: cox-2 inhibitors.Medsurg Nurs. 2000 Dec;9(6):313-7. Medsurg Nurs. 2000. PMID: 11904867 Review. No abstract available.
Cited by
-
Preparation and characterization of celecoxib dispersions in soluplus(®): comparison of spray drying and conventional methods.Iran J Pharm Res. 2015 Winter;14(1):35-50. Iran J Pharm Res. 2015. PMID: 25561910 Free PMC article.
-
In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration.AAPS PharmSciTech. 2010 Mar;11(1):85-9. doi: 10.1208/s12249-009-9364-5. Epub 2010 Jan 8. AAPS PharmSciTech. 2010. PMID: 20058106 Free PMC article.
-
Modeling of corneal and retinal pharmacokinetics after periocular drug administration.Invest Ophthalmol Vis Sci. 2008 Jan;49(1):320-32. doi: 10.1167/iovs.07-0593. Invest Ophthalmol Vis Sci. 2008. PMID: 18172109 Free PMC article.
-
Comparison of Hydroxypropyl Methylcellulose and Alginate Gel Films with Meloxicam as Fast Orodispersible Drug Delivery.Gels. 2023 Aug 25;9(9):687. doi: 10.3390/gels9090687. Gels. 2023. PMID: 37754368 Free PMC article.
-
Hydroxyapatite Nanorods Based Drug Delivery Systems for Bumetanide and Meloxicam, Poorly Water Soluble Active Principles.Nanomaterials (Basel). 2024 Jan 2;14(1):113. doi: 10.3390/nano14010113. Nanomaterials (Basel). 2024. PMID: 38202568 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials